February 18, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

 

NRG Oncology trial affirms hypofractionated radiotherapy should be considered new practice standard for men with low-risk prostate cancer.  Read more


 

AMENDMENTS
GENITOURINARY

RTOG 0924: Amendment 5, version date December 13, 2018 (posted to CTSU)


OTHER PROTOCOL NOTICES

1. COLORECTAL

NRG-GI002: Memo regarding Clarification of the Timing Requirement for Imaging on Table 2 (posted to CTSU)

2. CANCER PREVENTION & CONTROL

NRG-CC003: Study overview slides were posted to the CTSU website (Document > Education and Promotion).

 

NRG-CC004: An updated FSFI form has been approved by the CIRB. The document is posted on the CIRB Amendment tab of the CTSU website. Please use this version immediately.

3. GYNECOLOGIC

NRG-GY004 Data Freeze - March 2019

NRG-GY004 is maturing for the final analysis. Please ensure all data is up to date (including follow-up information), and all queries are answered. We expect to start the final analysis in March 2019. We will provide the results of this important study to you as soon as possible. If you have any questions please contact Sandy Dascomb at [ DascombS@NRGOncology.org].

 

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus

Please note that the NRG Patient ID (e.g., AB###-GY###-#####) must be included on any copies of Form TR shipped to the NRG Biospecimen Bank-Columbus. If the NRG Patient ID does not appear on the top, left of Form TR, please hand-complete the NRG Patient ID before sending the form to the NRG Biospecimen Bank-Columbus. Do not complete the NRG Patient ID for forms accompanying biospecimens shipped to laboratories other than the NRG Biospecimen Bank-Columbus. Please contact the NRG Biospecimen Bank-Columbus at bpcbank@nationwidechildrens.org  if you need assistance or have additional questions.

 

Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment

Please be advised that the data exchange between the Biospecimen Bank-Columbus and SDMC is undergoing refurbishment. During this time, biospecimen receipt information will not appear in Rave or SEDES. Biospecimen transmittal forms (i.e., Form SP and Form TR) will ultimately not appear as overdue during this time; however, there may be a brief period over the next several weeks during which forms may temporarily appear as overdue. If this should occur or if you experience any other issues, please notify Support at support@nrgoncology.org. Sites should continue to return inquiries from Biospecimen Bank-Columbus staff regarding biospecimen receipt during this time.

4. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for March 13, 2019.

 

 

DRUG SAFETY UPDATES AND INVESTIGATOR’S BROCHURE (IB) NOTICES

 

Safety updates and IB Notices have been issued for the following studies:

 

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

INVESTIGATOR'S BROCHURE (IB)*

Atezolimumab

NRG-GI004

CTSU

 

Ipilimumab

NRG-BN002

NRG-GY003

NRG

NRG

 

Lapatinib

RTOG-1119

 

 X

Olaparib

NRG-BN002

NRG-GY003

NRG

NRG

 

Pembrolizumab

NRG-GI002

CTSU

 

 

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website ( https://ctepcore.nci.nih.gov/OAOP/). Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.

 

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

 

 

NRG Oncology Trial Affirms Hypofractionated Radiotherapy Should be Considered New Practice Standard for Men with Low-risk Prostate Cancer

Results from the NRG Oncology clinical study NRG-RTOG 0415 determined that a hypofractionated radiotherapy schedule (H-RT), a treatment schedule that delivers a total dose of radiotherapy over a shorter period of time, is not worse than the conventional radiotherapy schedule (C-RT) in terms of bowel, bladder, sexual, and general quality of life (QOL), as well as anxiety and depression for men with low risk prostate cancer. Read the press release

 

Forbes: “How Social Media Can Advance Cancer Research”
In an article published in Forbes, Miriam Knoll, MD, writes about the importance of oncologists embracing the age of social media to increase patient awareness of and participation in clinical trials, including NRG Oncology's ongoing patient engagement efforts. Read more

 

President's Day Holiday Closures
The NRG Oncology Philadelphia East Operations Center and the Buffalo SDMC office locations will be closed for the President's Day holiday today, Monday, February 18, 2019 and will resume operations on Tuesday, February 19, 2019.  All other NRG Oncology locations will be open during regular business hours on President's Day.

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

 

JOURNAL ARTICLES

Bruner DW, Pugh SL, Lee WR, Dignam JJ, Low D, Swanson GP, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Nguyen PL, Hall WA, Pisansky TM, Chen Y, Sandler HM, Movsas B. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized

Clinical Trial. JAMA Oncol. 2019 Feb 14. doi: 10.1001/jamaoncol.2018.6752. [Epub ahead of print] PubMed PMID: 30763425. Read more

 

Matulonis UA, Sill MW, Makker V, Mutch DG, Carlson JW, Darus CJ, Mannel RS, Bender DP, Crane EK, Aghajanian C. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Dec 23. pii: S0090-8258(18)31460-4.  doi: 10.1016/j.ygyno.2018.12.008. [Epub ahead of print] PubMed PMID: 30587441.   Read more

 

PUBLICATIONS REMINDERS

Please note the following upcoming meeting and abstract submission deadline dates

 

Upcoming Meetings

American Association for Cancer Research (AACR); Mar 29 - Apr 3, 2019; Atlanta, GA

 

Society of Gynecologic Oncology (SGO); Mar 16-19, 2019; Honolulu, HI

 

Society of Surgical Oncology (SSO); Mar 27-30, 2019 ; San Diego, CA

 

St. Gallen Breast Cancer Conference (SG-BCC); Mar 20-23, 2019; Vienna, Austria

 

 

Upcoming Abstract Submission Deadlines

American Association of Physicists in Medicine (AAPM); Jul 14-18, 2019; San Antonio, TX; due to publications committee Feb 21, 2019; meeting submission deadline Mar 7, 2019

 

American Society of Clinical Oncology (ASCO); May 31 - Jun 4, 2019; Chicago, IL; LBA Mar 14, 2019 noon ET

 

American Society for Radiation Oncology (ASTRO); Sep 15-18, 2019; Chicago, IL; meeting submission deadline Feb 24, 2019

 

ESMO Breast Cancer Annual Congress; May 2-4, 2019; Berlin, Germany; LBA deadline Apr 1, 2019 noon CEST (Central European Summer Time)

 

International Society for Quality of Life Research (ISOQOL); Oct 20-23, 2019; San Diego, CA; due to publications committee Mar 26 2019; meeting submission deadline Apr 8, 2019

 

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse